Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes
Public ClinicalTrials.gov record NCT04319237. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to assess self-reported side effects and neurocognitive (brain, mood and thinking) functioning among patients treated with commercial axi-cel therapy.
Study identification
- NCT ID
- NCT04319237
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 60 participants
Conditions and interventions
Interventions
- Handgrip strength test Other
- Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR) Behavioral
- Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS) Behavioral
- Neuropsychological Assessment - Color Trails Behavioral
- Neuropsychological Assessment -Stroop Color and Word Test Behavioral
- Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Questionnaire Behavioral
- European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Behavioral
- Quality of Life (EQ-5D-5L) Questionnaire Behavioral
- PROMIS Cognitive Function 4a Questionnaire Behavioral
- Comprehensive Score for Financial Toxicity (COST) measure Behavioral
Other · Behavioral
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 10, 2020 (Actual)
- Primary completion
- Jul 14, 2023 (Actual)
- Completion
- Jul 31, 2023 (Actual)
- Last update posted
- Mar 2, 2026
2020 – 2023
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04319237, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 2, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04319237 live on ClinicalTrials.gov.